Lilly (LLY.US) recommends Elpida peptide as a weight loss drug by the UK regulatory agency.
The UK's National Institute for Health and Care Excellence has officially recommended the GLP-1 drug Tirzepatide from Lilly as a weight loss medication.
The UK's drug cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), has formally recommended Eli Lilly and Company's GLP-1 drug Tirzepatide as a weight loss medication. The drug is sold under the names Zepbound for weight loss and Moujaro for treating type 2 diabetes.
Due to anticipated high demand, NICE had earlier stated in December that Tirzepatide would be rolled out over a three-year period, with the "highest clinical need" patients being given priority for the drug.
Related Articles
US Stock Market Move | Capital Markets Day $23 Billion Target Falls Short of Expectations, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) Drops Over 8%
CF PHARMTECH (02652): ICF004 Completes Dosing of First Healthy Volunteer in Phase I Clinical Trial
US Stock Market Move | Paramount Skydance may clear acquisition hurdles; Warner Bros. Discovery (WBD.US) rises over 10%.
US Stock Market Move | Capital Markets Day $23 Billion Target Falls Short of Expectations, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) Drops Over 8%
CF PHARMTECH (02652): ICF004 Completes Dosing of First Healthy Volunteer in Phase I Clinical Trial
US Stock Market Move | Paramount Skydance may clear acquisition hurdles; Warner Bros. Discovery (WBD.US) rises over 10%.
RECOMMEND
